Compare Cardiol Therapeutics, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 168 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.14
-147.80%
6.95
Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2026)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.94%
0%
-5.94%
6 Months
-26.23%
0%
-26.23%
1 Year
-61.7%
0%
-61.7%
2 Years
56.77%
0%
56.77%
3 Years
-21.61%
0%
-21.61%
4 Years
-53.26%
0%
-53.26%
5 Years
-48.46%
0%
-48.46%
Cardiol Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-7.93%
EBIT to Interest (avg)
-30.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.32
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.15%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.95
EV to EBIT
-3.95
EV to EBITDA
-3.96
EV to Capital Employed
-41.01
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-147.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 93 Foreign Institutions (9.63%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.70
-8.00
-21.25%
Interest
0.00
0.00
Exceptional Items
-1.50
1.00
-250.00%
Consolidate Net Profit
-10.80
-7.20
-50.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -50.00% vs 28.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-34.20
-39.90
14.29%
Interest
0.00
0.00
Exceptional Items
1.00
0.20
400.00%
Consolidate Net Profit
-33.80
-36.70
7.90%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 7.90% vs -30.60% in Dec 2024
About Cardiol Therapeutics, Inc. 
Cardiol Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Company Coordinates 
Company Details
2275 Upper Middle Road East, Ste. 101 , OAKVILLE ON : L6H 0C3
Registrar Details






